The meeting’s abstracts point to studies from Merck & Co, Exelixis and others that should be on investors’ radar.
If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.
On the corporate front Astellas continued to buy, while Qiagen decided that it was not, after all, up for sale.
Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.
Non-US big biopharma stocks led the way in the third quarter, suggesting that those looking for investment gains would do best to search further afield.
China’s answer to the Asco conference, remarkably now in its 22nd year, reminds western investors of the country’s oncology prowess.
Astra’s Caspian study is the star of next week’s World Lung conference, which has also given targeted approaches important supporting roles.
Indulging in M&A is not the way to bump up share prices as oncology-focused companies prove to be the sector’s darlings.